Vitamin D Improves Selected Metabolic Parameters but Not Neuropsychological or Quality of Life Indices in OSA: A Pilot Study.
Study Goal
The researchers aimed to evaluate the effect of vitamin D supplementation on metabolic and neuropsychological outcomes in patients with obstructive sleep apnea (OSA).
Results Summary
Vitamin D supplementation significantly increased 25(OH)D levels and decreased low-density lipoprotein and lipoprotein-associated phospholipase A2, with trends toward improved fasting glucose and high-density lipoprotein. No changes were observed in BMI, medication use, CPAP usage, or neuropsychological/quality of life indices.
Population
Patients with obstructive sleep apnea (OSA).
Effective Dosage
4,000 IU daily.
Duration
Not specified in the abstract.
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
daily supplementation with 4,000 IU vitamin D | increase | 25(OH)D | patients with obstructive sleep apnea (OSA) | p = 0.00001 | significant increase | #1 |
daily supplementation with 4,000 IU vitamin D | decrease | low-density lipoprotein | patients with obstructive sleep apnea (OSA) | p = 0.04 | significant decreases | #2 |
daily supplementation with 4,000 IU vitamin D | decrease | lipoprotein-associated phospholipase A2 | patients with obstructive sleep apnea (OSA) | p = 0.037 | significant decreases | #3 |
daily supplementation with 4,000 IU vitamin D | decrease | fasting glucose | patients with obstructive sleep apnea (OSA) | p = 0.09 | trends toward decreased | #4 |
daily supplementation with 4,000 IU vitamin D | increase | high-density lipoprotein | patients with obstructive sleep apnea (OSA) | p = 0.07 | trends toward increased | #5 |
daily supplementation with 4,000 IU vitamin D | no change | BMI | patients with obstructive sleep apnea (OSA) | - | no change | #6 |
daily supplementation with 4,000 IU vitamin D | no change | medication | patients with obstructive sleep apnea (OSA) | - | no change | #7 |
daily supplementation with 4,000 IU vitamin D | no change | CPAP usage | patients with obstructive sleep apnea (OSA) | - | no change | #8 |
daily supplementation with 4,000 IU vitamin D | no change | neuropsychological indices | patients with obstructive sleep apnea (OSA) | - | no change | #9 |
daily supplementation with 4,000 IU vitamin D | no change | quality of life indices | patients with obstructive sleep apnea (OSA) | - | no change | #10 |
STUDY OBJECTIVES: Our group and others have reported a high rate of vitamin D deficiency in obstructive sleep apnea (OSA), where vitamin D levels (25(OH) D) correlate negatively with OSA severity and some of its associated metabolic alterations. Data regarding vitamin D supplementation in OSA are lacking. We wanted to evaluate the effect of vitamin D METHODS: We conducted a pilot, double-blind, randomized, placebo-controlled trial of daily supplementation with 4,000 IU vitamin D RESULTS: There was no change in BMI, medication, or CPAP usage. Although there was no change in neuropsychological or quality of life indices, we observed a significant increase in 25(OH)D (p = 0.00001) and significant decreases in both low-density lipoprotein (p = 0.04) and lipoprotein-associated phospholipase A2 (p = 0.037) as well as trends toward decreased fasting glucose (p = 0.09) and increased high-density lipoprotein (p = 0.07) in the D CONCLUSIONS: Vitamin D